ArticleGastro hep advances2025
Early-Onset Colorectal Cancer Survival by Race and Ethnicity in a Large Community-Based Insured Population.
Article in Gastro hep advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cancer Screening and Citizenship Status in the US.JAMA network open · 2026Article
- Exploring the role of marital status on survival and stage at diagnosis in early-onset colorectal cancer by race/ethnicity.Scientific reports · 2026Article
- Integrated transcriptomic profiling reveals immune and molecular stage-specific signatures of colorectal cancer in hispanics living in Puerto Rico.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Colorectal cancer (CRC) incidence in those under age 50 is increasing and minority populations are known to have worse CRC survival outcomes. Therefore, we evaluated 5-year CRC-specific survival by race and ethnicity among medically insured patients with early-onset CRC. Methods: This retrospective cohort study included Kaiser Permanente Northern California patients aged 18-49 years diagnosed with CRC between 2006 and 2019. Five-year CRC-specific survival by race and ethnicity was assessed using Kaplan-Meier survival analyses and unadjusted and adjusted Cox proportional hazards models. Results: Among 1620 patients, 50.3% were White, 21.6% Hispanic, 20.1% Asian or Pacific Islander, and 8.0% Black. Stage IV disease was found in 23.4% of White, 28.7% of Black, 30.1% of Asian or Pacific Islander, and 31.1% of Hispanic patients. Five-year CRC-specific survival probability estimates ranged from 74.4% in Hispanic patients to 79.9% in White patients with no statistically significant differences in unadjusted risk estimates. However, after adjusting for age, sex, comorbidities, and socioeconomic status measures, risk of death was higher in Hispanic vs White patients (hazard ratio: 1.46; 95% confidence interval: 1.08-1.97) but was attenuated (hazard ratio: 1.13; 95% confidence interval: 0.83-1.53) after further adjustment for stage at diagnosis. Conclusion: Among medically insured patients in a large integrated healthcare setting, Hispanic patients were more likely to be diagnosed with stage IV CRC and had the lowest 5-year CRC-specific survival probability compared to other race groups. Additional research is needed to identify factors contributing to the higher rate of late-stage disease diagnosis in Hispanic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.